Contact

Get in touch with Gesynta Pharma

Gesynta Pharma AB
Wallingatan 24
SE-111 24 Stockholm


LinkedIn

Learn more about Gesynta Pharma

Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.

Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.

Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.

Our lead drug candidate GS-248 is currently under evaluation in a phase 2 study.